Comparison of Long- and Short-acting Diuretics in Congestive Heart Failure

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare therapeutic effects of furosemide, a short-acting loop diuretic, and azosemide, a long-acting one, in patients with heart failure, and to test our hypothesis that long-acting diuretics are superior to short-acting types in heart failure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hyogo College of Medicine
• Collaborator: Ministry of Health, Labour and Welfare, Japan
• Treatments: Azosemide; Diuretics; Furosemide; Sulfanilamides

Criteria

Inclusion Criteria:

• Clinical diagnosis of heart failure based on a slight modification of the Framingham criteria as previously described within 6 months before the entry

• Current status of heart failure is NYHA II or III.

• Currently, loop diuretic(s) is (are) administered.

• No change in baseline therapy and symptoms of heart failure within a month

Exclusion Criteria:

• Current symptomatic hypotension

• Hypertension that has not been controlled to the satisfaction of the investigator

• Hemodynamically significant (in the investigators opinion) LV outflow tract obstruction (due to either aortic stenosis or ventricular hypertrophy)

• Acute coronary syndrome

• Primary pulmonary hypertension or pulmonary hypertension not due to LV dysfunction

• Serious cerebrovascular disease

• Acute myocardial infarction within the last 3 months

• Patients who require intravenous inotropes

• Cerebrovascular accident within the last 3 months

• Percutaneous coronary intervention or open heart surgery within the last 3 months

• On the waiting list for percutaneous coronary intervention or open heart surgery

• Serum creatinine > 2.5 mg/dl

• Serious liver disease

• Any change in cardiovascular drug therapy within a month prior to randomization

• History of chronic obstructive pulmonary disease or restrictive lung disease

• Diabetes mellitus that has not been well controlled (fasting blood glucose>200 mg/dl、HbA1c > 8%)

• Any life-threatening acute disease

• Patients with implantable cardiac defibrillator

• Other diseases likely to cause death or serious disability during the period of the study

• Patients unable to walk without personal aid